Released Mar 11, 2025, before the open
10-K filed Mar 11, 2025, 70 days after period end · 0001785530-25-000008
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$20.40M-$20.40M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$20,348,000N/M
Operating Cash Flowderived-$14,252,000N/M
Free Cash Flowderived-$14,375,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$20.40M | -$12.00M | -$11.93M | -$17.87M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR